Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States.
Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, Colucci P, Mesa R. Grunwald MR, et al. Among authors: stein bl. Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):788-795.e2. doi: 10.1016/j.clml.2018.08.009. Epub 2018 Aug 29. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30245100 Free PMC article.
Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR. Stein BL, et al. Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591. Epub 2011 Jun 28. Haematologica. 2011. PMID: 21712540 Free PMC article.
Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease.
Tabarroki A, Visconte V, Rogers HJ, Sekeres MA, Samaras C, Lichtin A, Duong HK, Englehaupt R, Cinalli T, Dodd K, Desamito J, Rouphail B, Altman JK, Stein BL, Tiu RV. Tabarroki A, et al. Among authors: stein bl. Leuk Lymphoma. 2014 Jan;55(1):213-6. doi: 10.3109/10428194.2013.797086. Epub 2013 Jun 12. Leuk Lymphoma. 2014. PMID: 23607256 No abstract available.
AKT is a therapeutic target in myeloproliferative neoplasms.
Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke CM, Lasho TL, Koppikar P, Pardanani A, Stein B, Altman JK, Levine RL, Tefferi A, Crispino JD. Khan I, et al. Leukemia. 2013 Sep;27(9):1882-90. doi: 10.1038/leu.2013.167. Epub 2013 Jun 10. Leukemia. 2013. PMID: 23748344 Free PMC article.
Novel therapies for myelofibrosis.
Stein BL, Cervantes F, Giles F, Harrison CN, Verstovsek S. Stein BL, et al. Leuk Lymphoma. 2015;56(10):2768-78. doi: 10.3109/10428194.2015.1037762. Epub 2015 May 18. Leuk Lymphoma. 2015. PMID: 25860240 Free PMC article. Review.
105 results